Equities research analysts at Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a report issued on Thursday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

AGIO has been the topic of a number of other reports. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, June 11th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Janney Montgomery Scott restated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. Finally, ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $74.75.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down 0.35% on Thursday, hitting $65.59. The stock had a trading volume of 237,681 shares. The stock has a 50 day moving average of $59.52 and a 200 day moving average of $54.17. The firm’s market cap is $3.17 billion. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. During the same quarter last year, the company earned ($1.47) earnings per share. The firm’s revenue for the quarter was up 62.1% on a year-over-year basis. Equities analysts predict that Agios Pharmaceuticals will post ($7.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Agios Pharmaceuticals, Inc. (AGIO) Earns Outperform Rating from Analysts at Royal Bank Of Canada” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/agios-pharmaceuticals-inc-agio-earns-outperform-rating-from-analysts-at-royal-bank-of-canada.html.

In other Agios Pharmaceuticals news, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $55.00, for a total value of $118,030.00. Following the sale, the insider now directly owns 8,410 shares in the company, valued at $462,550. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David P. Schenkein sold 3,000 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $51.18, for a total value of $153,540.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares in the company, valued at $153,540. The disclosure for this sale can be found here. Over the last quarter, insiders sold 99,230 shares of company stock worth $5,918,142. Insiders own 10.55% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its stake in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at $129,000. QS Investors LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at $144,000. Russell Investments Group Ltd. raised its stake in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares in the last quarter. Institutional investors own 94.30% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

The Fly

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.